These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 27755520)
21. Exposure to kynurenic acid during adolescence produces memory deficits in adulthood. Akagbosu CO; Evans GC; Gulick D; Suckow RF; Bucci DJ Schizophr Bull; 2012 Jun; 38(4):769-78. PubMed ID: 21172906 [TBL] [Abstract][Full Text] [Related]
22. Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia. Bencherif M; Stachowiak MK; Kucinski AJ; Lippiello PM Med Hypotheses; 2012 May; 78(5):594-600. PubMed ID: 22336089 [TBL] [Abstract][Full Text] [Related]
23. Kynurenic Acid/AhR Signaling at the Junction of Inflammation and Cardiovascular Diseases. Grishanova AY; Perepechaeva ML Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000041 [TBL] [Abstract][Full Text] [Related]
24. Endogenous kynurenic acid regulates extracellular GABA levels in the rat prefrontal cortex. Beggiato S; Tanganelli S; Fuxe K; Antonelli T; Schwarcz R; Ferraro L Neuropharmacology; 2014 Jul; 82():11-8. PubMed ID: 24607890 [TBL] [Abstract][Full Text] [Related]
25. Long-term exposure to nicotine markedly reduces kynurenic acid in rat brain--in vitro and ex vivo evidence. Zielińska E; Kuc D; Zgrajka W; Turski WA; Dekundy A Toxicol Appl Pharmacol; 2009 Oct; 240(2):174-9. PubMed ID: 19616570 [TBL] [Abstract][Full Text] [Related]
26. Prenatal Dynamics of Kynurenine Pathway Metabolism in Mice: Focus on Kynurenic Acid. Goeden N; Notarangelo FM; Pocivavsek A; Beggiato S; Bonnin A; Schwarcz R Dev Neurosci; 2017; 39(6):519-528. PubMed ID: 29080891 [TBL] [Abstract][Full Text] [Related]
27. Kynurenate production by cultured human astrocytes. Kiss C; Ceresoli-Borroni G; Guidetti P; Zielke CL; Zielke HR; Schwarcz R J Neural Transm (Vienna); 2003 Jan; 110(1):1-14. PubMed ID: 12541009 [TBL] [Abstract][Full Text] [Related]
28. Prenatal kynurenine exposure in rats: age-dependent changes in NMDA receptor expression and conditioned fear responding. Pershing ML; Phenis D; Valentini V; Pocivavsek A; Lindquist DH; Schwarcz R; Bruno JP Psychopharmacology (Berl); 2016 Oct; 233(21-22):3725-3735. PubMed ID: 27527585 [TBL] [Abstract][Full Text] [Related]
29. Tryptophan challenge in individuals with schizophrenia and healthy controls: acute effects on circulating kynurenine and kynurenic acid, cognition and cerebral blood flow. Hare SM; Adhikari BM; Mo C; Chen S; Wijtenburg SA; Seneviratne C; Kane-Gerard S; Sathyasaikumar KV; Notarangelo FM; Schwarcz R; Kelly DL; Rowland LM; Buchanan RW Neuropsychopharmacology; 2023 Oct; 48(11):1594-1601. PubMed ID: 37118058 [TBL] [Abstract][Full Text] [Related]
30. Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy. Silva-Adaya D; Pérez-De La Cruz V; Villeda-Hernández J; Carrillo-Mora P; González-Herrera IG; García E; Colín-Barenque L; Pedraza-Chaverrí J; Santamaría A Neurotoxicol Teratol; 2011; 33(2):303-12. PubMed ID: 20933078 [TBL] [Abstract][Full Text] [Related]
31. Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. Plitman E; Iwata Y; Caravaggio F; Nakajima S; Chung JK; Gerretsen P; Kim J; Takeuchi H; Chakravarty MM; Remington G; Graff-Guerrero A Schizophr Bull; 2017 Jul; 43(4):764-777. PubMed ID: 28187219 [TBL] [Abstract][Full Text] [Related]
32. Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis. Linderholm KR; Andersson A; Olsson S; Olsson E; Snodgrass R; Engberg G; Erhardt S Neuropharmacology; 2007 Dec; 53(8):918-24. PubMed ID: 17959203 [TBL] [Abstract][Full Text] [Related]
33. Relevance of Alternative Routes of Kynurenic Acid Production in the Brain. Ramos-Chávez LA; Lugo Huitrón R; González Esquivel D; Pineda B; Ríos C; Silva-Adaya D; Sánchez-Chapul L; Roldán-Roldán G; Pérez de la Cruz V Oxid Med Cell Longev; 2018; 2018():5272741. PubMed ID: 29977455 [TBL] [Abstract][Full Text] [Related]
34. [Mechanisms of neurocognitive deficit development in schizophrenia and current treatment approaches]. Petrova NN; Dorofeykova MV Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):116-23. PubMed ID: 25629134 [TBL] [Abstract][Full Text] [Related]
35. Possibility of Amino Acid Treatment to Prevent the Psychiatric Disorders via Modulation of the Production of Tryptophan Metabolite Kynurenic Acid. Fukuwatari T Nutrients; 2020 May; 12(5):. PubMed ID: 32414200 [TBL] [Abstract][Full Text] [Related]
36. Linking phencyclidine intoxication to the tryptophan-kynurenine pathway: Therapeutic implications for schizophrenia. Fujigaki H; Mouri A; Yamamoto Y; Nabeshima T; Saito K Neurochem Int; 2019 May; 125():1-6. PubMed ID: 30731185 [TBL] [Abstract][Full Text] [Related]
37. Kynurenic acid and schizophrenia. Erhardt S; Schwieler L; Engberg G Adv Exp Med Biol; 2003; 527():155-65. PubMed ID: 15206728 [TBL] [Abstract][Full Text] [Related]